• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

OXAZEPAM Drug Record

  • Summary
  • Interactions
  • Claims
  • OXAZEPAM chembl:CHEMBL568 Approved

    Alternate Names:

    TEMAZEPAM IMPURITY, OXAZEPAM-
    OXOZEPAM
    OXAZEPAM CIV
    SERAX
    WY-3498
    J3.308A
    SERENID FTE
    ZAXOPAM
    OXAZEPAM
    LEDERPAM
    NSC-169448
    TAZEPAM
    (+-)-OXAZEPAM
    (RS)-OXAZEPAM
    SERAX®
    chembl:CHEMBL568
    rxcui:7781
    chemidplus:604-75-1
    pubchem.compound:4616
    drugbank:00842

    Drug Info:

    FDA Approval 1965
    Drug Class small molecule
    Drug Indications Hypnotics and Sedatives
    Year of Approval 1965
    Drug Class hypnotics and sedatives
    (3 More Sources)

    Publications:

    Möhler et al., 2002, A new benzodiazepine pharmacology., J. Pharmacol. Exp. Ther.
    Riss et al., 2008, Benzodiazepines in epilepsy: pharmacology and pharmacokinetics., Acta Neurol. Scand.
    Zhu S et al., 2018, Structure of a human synaptic GABA<sub>A</sub> receptor., Nature
    Sigel E et al., 2012, Structure, function, and modulation of GABA(A) receptors., J Biol Chem
    Bhatt DK et al., 2019, Age- and Genotype-Dependent Variability in the Protein Abundance and Activity of Six Major Uridine Diphosphate-Glucuronosyltransferases in Human Liver., Clin Pharmacol Ther
    Court MH et al., 2004, UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver., J Pharmacol Exp Ther
  • OXAZEPAM   UGT2B15

    Interaction Score: 1.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29737521 15044558


    Sources:
    PharmGKB

  • OXAZEPAM   GABRR2

    Interaction Score: 0.38

    Interaction Types & Directionality:
    potentiator

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    11752090 18384456


    Sources:
    TdgClinicalTrial TEND

  • OXAZEPAM   GABRR3

    Interaction Score: 0.38

    Interaction Types & Directionality:
    potentiator

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    11752090 18384456


    Sources:
    TdgClinicalTrial TEND

  • OXAZEPAM   GABRR1

    Interaction Score: 0.35

    Interaction Types & Directionality:
    potentiator

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    11752090 18384456


    Sources:
    TdgClinicalTrial TEND

  • OXAZEPAM   GABRQ

    Interaction Score: 0.22

    Interaction Types & Directionality:
    positive modulator (activating)
    potentiator

    Interaction Info:
    Trial Name -
    Novel drug target Established target
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator

    PMIDs:
    11752090 18384456


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • OXAZEPAM   GABRP

    Interaction Score: 0.2

    Interaction Types & Directionality:
    positive modulator (activating)
    potentiator

    Interaction Info:
    Novel drug target Established target
    Trial Name -
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator

    PMIDs:
    11752090 18384456


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • OXAZEPAM   GABRE

    Interaction Score: 0.2

    Interaction Types & Directionality:
    positive modulator (activating)
    potentiator

    Interaction Info:
    Trial Name -
    Novel drug target Established target
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator

    PMIDs:
    11752090 18384456


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • OXAZEPAM   GABRD

    Interaction Score: 0.19

    Interaction Types & Directionality:
    positive modulator (activating)
    potentiator

    Interaction Info:
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator
    Direct Interaction yes
    Trial Name -

    PMIDs:
    11752090 18384456


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • OXAZEPAM   GABRG1

    Interaction Score: 0.19

    Interaction Types & Directionality:
    positive modulator (activating)
    potentiator

    Interaction Info:
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator
    Direct Interaction yes
    Trial Name -

    PMIDs:
    11752090 18384456


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • OXAZEPAM   GABRB3

    Interaction Score: 0.19

    Interaction Types & Directionality:
    positive modulator (activating)
    potentiator

    Interaction Info:
    Novel drug target Established target
    Trial Name -
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator

    PMIDs:
    11752090 18384456


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • OXAZEPAM   GABRB1

    Interaction Score: 0.19

    Interaction Types & Directionality:
    positive modulator (activating)
    potentiator

    Interaction Info:
    Novel drug target Established target
    Trial Name -
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator

    PMIDs:
    11752090 18384456


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • OXAZEPAM   GABRA1

    Interaction Score: 0.18

    Interaction Types & Directionality:
    ligand
    positive modulator (activating)
    potentiator

    Interaction Info:
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator
    Direct Interaction yes
    Trial Name -

    PMIDs:
    11752090 18384456 29950725 23038269


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • OXAZEPAM   GABRA4

    Interaction Score: 0.18

    Interaction Types & Directionality:
    positive modulator (activating)
    potentiator

    Interaction Info:
    Trial Name -
    Novel drug target Established target
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator

    PMIDs:
    11752090 18384456


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • OXAZEPAM   GABRA6

    Interaction Score: 0.18

    Interaction Types & Directionality:
    positive modulator (activating)
    potentiator

    Interaction Info:
    Trial Name -
    Novel drug target Established target
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator

    PMIDs:
    11752090 18384456


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • OXAZEPAM   GABRB2

    Interaction Score: 0.17

    Interaction Types & Directionality:
    positive modulator (activating)
    potentiator

    Interaction Info:
    Novel drug target Established target
    Trial Name -
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator

    PMIDs:
    11752090 18384456


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • OXAZEPAM   GABRG3

    Interaction Score: 0.17

    Interaction Types & Directionality:
    positive modulator (activating)
    potentiator

    Interaction Info:
    Trial Name -
    Novel drug target Established target
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator

    PMIDs:
    11752090 18384456


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • OXAZEPAM   GABRA5

    Interaction Score: 0.16

    Interaction Types & Directionality:
    positive modulator (activating)
    potentiator

    Interaction Info:
    Novel drug target Established target
    Trial Name -
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator

    PMIDs:
    11752090 18384456


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • OXAZEPAM   GABRA3

    Interaction Score: 0.16

    Interaction Types & Directionality:
    positive modulator (activating)
    potentiator

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator
    Trial Name -

    PMIDs:
    11752090 18384456


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • OXAZEPAM   GABRA2

    Interaction Score: 0.15

    Interaction Types & Directionality:
    positive modulator (activating)
    potentiator

    Interaction Info:
    Trial Name -
    Novel drug target Established target
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator

    PMIDs:
    11752090 18384456


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • OXAZEPAM   GABRG2

    Interaction Score: 0.14

    Interaction Types & Directionality:
    positive modulator (activating)
    potentiator

    Interaction Info:
    Mechanism of Interaction GABA-A receptor; anion channel positive allosteric modulator
    Direct Interaction yes

    PMIDs:
    11752090 18384456


    Sources:
    ChemblInteractions TEND

  • OXAZEPAM   UGT1A9

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • OXAZEPAM   UGT2B7

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • OXAZEPAM   TSPO

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • OXAZEPAM   CYP2C19

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • OXAZEPAM   AR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • OXAZEPAM   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TEND: OXAZEPAM

    • Version: 01-August-2011

    Alternate Names:
    OXAZEPAM Primary Drug Name

    Drug Info:
    Drug Class hypnotics and sedatives
    Year of Approval 1965

    Publications:

  • TdgClinicalTrial: OXAZEPAM

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Hypnotics and Sedatives
    Drug Class small molecule
    FDA Approval 1965

    Publications:

  • PharmGKB: oxazepam

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Court MH et al., 2004, UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver., J Pharmacol Exp Ther
    Bhatt DK et al., 2019, Age- and Genotype-Dependent Variability in the Protein Abundance and Activity of Six Major Uridine Diphosphate-Glucuronosyltransferases in Human Liver., Clin Pharmacol Ther

  • DTC: OXAZEPAM

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL568 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Oxazepam

    • Version: 2020.06.01

    Alternate Names:
    D09LDR TTD Drug ID

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL568

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL568

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21